Page 96 - GHES-1-1

Global Health Econ Sustain Impact of new drug indications in Brazil

Da Veiga, C.R.P., da Veiga, C.P., & Drummond-Lage, A.P. INCA. (2022). INCA Estima 704 Mil Casos de Câncer Por Ano
(2018). Concern over cost of and access to cancer no Brasil Até 2025. Instituto Nacional de Câncer-INCA.
treatments: A meta-narrative review of nivolumab and Available from: https://www.gov.br/inca/pt-br/assuntos/
pembrolizumab studies. Critical Reviews in Oncology/ noticias/2022/inca-estima-704-mil-casos-de-cancer-por-
Hematology, 129:133-145. ano-no-brasil-ate-2025 [Last accessed on 2023 Apr 25].
https://doi.org/10.1016/j.critrevonc.2018.07.002 Ivama-Brummell, A.M., Pingret-Kipman, D., Louly, P.G., &
Andrade, R.R. (2022). Medicines regulation, pricing and
Daiichi Sankyo. (2023). ENHERTU (Fam-trastuzumab reimbursement in Brazil. Revista Brasileira de Farmácia
®
Deruxtecan-nxki) Official Patient Website. Available from:
https://www.enhertu.com [Last accessed on 2023 Jan 01]. Hospitalar e Serviços de Saúde, 13(1):769.
https://doi.org/10.30968/rbfhss.2022.131.0769
De Farias, M., & Pinto, M.F.T. (2021). Criteria for setting drug
prices in Brazil and selected countries: a comparative review. Keam, S.J. (2020). Trastuzumab deruxtecan: First approval.
Brazilian Journal of Health Economics, 13(3):322-337. Drugs, 80(5):501-508.
https://doi.org/10.21115/JBES.v13.n3.p322-37 https://doi.org/10.1007/s40265-020-01281-4
Destiny Clinical Trials. (2023). DESTINY Clinical Trials Kerr, S., Jazieh, A.R., & Kerr, D. (2017). How useful are
for Metastatic Breast Cancer. Available from: https:// international treatment guidelines in low-and middle-
destinyclinicaltrials.com/en [Last accessed on 2023 Jan 01]. income countries? Journal of Global Oncology, 3(5):441-443.
Dos Santos Dias, L.L., dos Santos, M.A.B., & Pinto, C.D.B.S. https://doi.org/10.1200/JGO.2016.008250
(2019). Contemporary regulation of drug prices in Brazil - a Keytruda HCP. (2023). Selected Indications for KEYTRUDA
®
critical analysis. Saúde Em Debate, 43(121):543-558.
(Pembrolizumab). Available from: https://www.
https://doi.org/10.1590/0103-1104201912120 keytrudahcp.com/approved-indications [Last accessed on
2023 Jan 20].
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C.,
Rebelo, M., et al. (2015). Cancer incidence and mortality Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M.,
worldwide: Sources, methods and major patterns in De Jesus-Acosta, A., Delord, J.P., et al. (2020). Efficacy
GLOBOCAN 2012. International Journal of Cancer, of pembrolizumab in patients with noncolorectal high
136(5):E359-E386. microsatellite instability/mismatch repair-deficient cancer:
Results from the phase II KEYNOTE-158 study. Journal of
https://doi.org/10.1002/ijc.29210
Clinical Oncology, 38(1):1-10.
Franken, M., Heintz, E., Gerber-Grote, A., & Raftery, J. (2016). https://doi.org/10.1200/JCO.19.02105
Health economics as rhetoric: The limited impact of health
economics on funding decisions in four European countries. Ministério da Saúde. (2023). Sistema de Informações Sobre
Value in Health, 19(8):951-956. Orçamentos Públicos em Saúde-SIOPS. Ministério da
Saúde. Available from: https://www.gov.br/saude/pt-br/
https://doi.org/10.1016/j.jval.2016.08.001
acesso-a-informacao/siops/sistema-de-informacoes-sobre-
Gammie, T., Lu, C.Y., & Babar, Z.U.D. (2015). Access to orphan orcamentos-publicos-em-saude-siops [Last accessed on
drugs: A comprehensive review of legislations, regulations 2023 Jul 11].
and policies in 35 countries. PLoS One, 10(10):e0140002.
Modi, S., Saura, C., Yamashita, T., Park, Y.H., Kim, S.B.,
https://doi.org/10.1371/journal.pone.0140002 Tamura, K., et al. (2020). Trastuzumab deruxtecan in
previously treated HER2-positive breast cancer. TheNew
Goldstein, D.A., Stemmer, S.M., & Gordon, N. (2016). The cost
and value of cancer drugs-are new innovations outpacing England Journal of Medicine, 382(7):610-621.
our ability to pay? Israel Journal of Health Policy Research, https://doi.org/10.1056/NEJMoa1914510
5(1):40.
MSD. (2023). KEYTRUDA (Pembrolizumab). Available from:
®
https://doi.org/10.1186/s13584-016-0097-0 https://www.keytruda.com [Last accessed on 2023 Jan 20].
Grand View Research. (2023). Pharmaceutical Manufacturing OECD. (2023). Exchange Rates (Indicator). Doi:
Market Size Report, 2021-2028. Available from: https://www. 10.1787/037ed317-en Available from: https://data.oecd.
grandviewresearch.com/industry-analysis/pharmaceutical- org/conversion/exchange-rates.htm [Last accessed on
manufacturing-market [Last accessed on 2023 Apr 27]. 2023 Feb 02].
Howard, D.H., Bach, P.B., Berndt, E.R., & Conti, R.M. (2015). Sharma, A., Jacob, A., Tandon, M., & Kumar, D. (2010). Orphan
Pricing in the market for anticancer drugs. Journal of drug: Development trends and strategies. Journal of
Economic Perspectives, 29(1):139-162. Pharmacy and Bioallied Sciences, 2(4):290-299.
https://doi.org/10.1257/jep.29.1.139 https://doi.org/10.4103/0975-7406.72128

Volume 1 Issue 1 (2023) 9 https://doi.org/10.36922/ghes.0994